Connective tissue growth factor antisense oligonucleotides
AssigneeFibroGen, Inc.
InventorsMark D. Sternlicht, Todd W. Seeley
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
Claims14
A modified antisense oligonucleotide, 12 to 20 nucleotides in length, that is complementary to a region of human connective tissue growth factor (CTGF) mRNA and comprises at least 12 consecutive nucleotides of an oligonucleotide selected from the group consisting of SEQ ID NO:
- 273, SEQ ID NO:
- 274, SEQ ID NO:
- 275, SEQ ID NO:
- 232, SEQ ID NO:
- 106, SEQ ID NO:
- 233 and SEQ ID NO:
- 276.
A modified antisense oligonucleotide between 12 and 30 nucleotides in length that is complementary to a region within nucleotides 1185 to 1216 of SEQ ID NO:1.
A modified antisense oligonucleotide selected from the group consisting of SEQ ID NO:
- 105, SEQ ID NO:
- 230, SEQ ID NO 231, SEQ ID NO:
- 273, SEQ ID NO:
- 274, SEQ ID NO:
- 275, SEQ ID NO:
- 232, SEQ ID NO:
- 106, SEQ ID NO:
- 233 and SEQ ID NO:
- 276.
A method of treating a CTGF-associated disorder comprising, administering to a subject in need thereof, an effective amount of a modified antisense oligonucleotide, 12 to 30 nucleotides in length, that is complementary to a region within nucleotides 1185 to 1216 of SEQ ID NO:
- 1, thereby treating the CTGF-associated disorder.
Dependencies are inferred from the claim text.